$0.98
-0.01 (-0.90%)
Open$1.01
Previous Close$0.99
Day High$1.01
Day Low$0.98
52W High$1.27
52W Low$0.27
Volume—
Avg Volume332.9K
Market Cap49.09M
P/E Ratio—
EPS$-0.73
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+4,014.3% upside
Current
$0.98
$0.98
Target
$40.32
$40.32
$26.90
$40.32 avg
$53.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.73M | 5.14M | 4.74M |
| Net Income | -102,176,432 | 951.6K | 665.5K |
| Profit Margin | -3,740.9% | 18.5% | 14.0% |
| EBITDA | -102,471,540 | 1.31M | 1.24M |
| Free Cash Flow | — | 380.5K | 530.0K |
| Rev Growth | — | -9.9% | +8.5% |
| Debt/Equity | 0.36 | 0.11 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |